Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.56 |
| ▸ | F10 | P00742 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | NOS3 | P29474 | 2/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.47 |
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253164 | 1.00 | LOXL2 (0.56) | LOXL2F10RAB9AGAAKDM1A | |
| SCHEMBL5154701 | 1.00 | LOXL2 (0.56) | LOXL2F10RAB9AGAAKDM1A | |
| Hydrochloric Acid SCHEMBL6743119 | 0.98 | LOXL2 (0.54) | LOXL2F10RAB9AGAAKDM1A | |
| Hydrochloric Acid SCHEMBL18300738 | 0.98 | LOXL2 (0.54) | LOXL2F10RAB9AGAAKDM1A | |
| Hydrochloric Acid SCHEMBL6743124 | 0.98 | LOXL2 (0.54) | LOXL2F10RAB9AGAAKDM1A | |
| Hydrochloric Acid SCHEMBL18300737 | 0.98 | LOXL2 (0.54) | LOXL2F10RAB9AGAAKDM1A | |
| SCHEMBL6651592 | 0.83 | TAAR1 (0.50) | LOXL2RAB9AGAAKDM1ANOS3 | |
| SCHEMBL21215222 | 0.83 | KDM1A (0.60) | RAB9AGAAKDM1ANPC1LMNA | |
| SCHEMBL320861 | 0.82 | PRSS1 (0.56) | RAB9AGAAKDM1ANOS3NOS1 | |
| SCHEMBL320862 | 0.82 | PRSS1 (0.56) | RAB9AGAAKDM1ANOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194780-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9815853-B2 | Bridged bicyclic kallikrein inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20090227559-A1 | SNPS IN THE APOB GENE AND SUSCEPTIBILITY TO INCREASED LEVELS OF ALAT FOLLOWING XIMELAGATRAN ADMINISTRATION | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090054394-A1 | POLYMORPHISMS IN MGST3 ARE ASSOCIATED WITH ELEVATED ALAT LEVELS AFTER XIMELAGATRAN TREATMENT | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-20090036424-A1 | ASSOCIATION BETWEEN HLA-DRBI*07 ALLELE AND SUSCEPTIBILY TO INCREASED LEVELS OF ALAT FOLLOWING XIMELAGATRAN ADMINISTRATION | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-20090029367-A1 | POLYMORPHISMS IN PON1 ARE ASSOCIATED WITH ELEVATED ALANINE AMINOTRANSFERASE LEVELS AFTER XIMELAGATRAN OR TACRINE ADMINISTRATION | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-1937843-A1 | POLYMORPHISMS IN PONl ARE ASSOCIATED WITH ELEVATED ALANINE AMINOTRANSFERASE LEVELS AFTER XIMELAGATRAN OR TACRINE ADMINISTRATION | Astra Zeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| EP-1937841-A1 | POLYMORPHISMS IN MGST3 ARE ASSOCIATED WITH ELEVATED ALAT LEVELS AFTER XIMELAGATRAN TREATMENT | Astra Zeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| EP-1934371-A1 | SNPS IN THE APOB GENE AND SUSCEPTIBILITY TO INCREASED LEVELS OF ALAT FOLLOWING XIMELAGATRAN ADMINISTRATION | AstraZeneca AB (SE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039724-A1 | SNPS IN THE APOB GENE AND SUSCEPTIBILITY TO INCREASED LEVELS OF ALAT FOLLOWING XIMELAGATRAN ADMINISTRATION | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039718-A1 | POLYMORPHISMS IN MGST3 ARE ASSOCIATED WITH ELEVATED ALAT LEVELS AFTER XIMELAGATRAN TREATMENT | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039722-A1 | POLYMORPHISMS IN PONl ARE ASSOCIATED WITH ELEVATED ALANINE AMINOTRANSFERASE LEVELS AFTER XIMELAGATRAN OR TACRINE ADMINISTRATION | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194780-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK2 | LOXL2 1090/4885F10 544/4885RAB9A 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.